The global viral vector manufacturing market is expected to grow at a CAGR of 19.4% during the forecast period 2021-2027. The rising research base for innovative medicines has principally driven the industry for clinical applications, including clinical, preclinical, and regulatory studies.
The COVID-19 pandemic has generated a lucrative opportunity for market participants, specifically in the vaccine production industry. The increasing significance of stem cell technology and the growing focus on cell and gene therapies will further propel the viral vector manufacturing market growth over the coming years.
Research in gene and cell therapy has gained prominence in the past few decades. Many such therapies use viral strands to deliver the specific gene that is expected to mitigate the genetic disorders. Gene therapy provides the potential to cure various diseases that include heart disease, diabetes, hemophilia, cancer, cystic fibrosis, and AIDS.
Request To Download Free Sample of This Strategic Report @https://reportocean.com/industry-verticals/sample-request?report_id=BWCC635
The number of gene treatments in the pipeline is over 360 in the U.S. alone, and more than 75% of these new therapies are still in an early stage of research & development. This will help the market growth for viral vector production.
COVID-19 pandemic is expected to positively influence the market’s growth for Viral vector manufacturing during the forecast period since these tracks are used in the R&D of COVID-19 vaccines. The adenoviral vector Ad5 is already being explored in the R&D of the COVID-19 vaccine, and this cost-effective approach has already been used for the production of the Ebola virus vaccine.
Growth Drivers
The global market for Viral vector manufacturing is driven by factors such as the increased R&D in cell and gene therapy in recent years, along with the adoption of these paths in developing vaccines and oncolytic therapies. The rapid use of stem cells in disease modeling and the emergence of the COVID-19 pandemic are expected further to propel the market growth for Viral vector manufacturing during the forecast period.
Stem cell technology has seen rapid progress in recent years and induced pluripotent stem cell (iPSC) is the fastest growing stem cell segment with approximately 10% growth every year. The lentiviral segment is commonly utilized in the generation of iPSC.
Induced pluripotent cells (iPSC cells) are utilized in disease modeling and will help in the better understanding of the pathogenesis of various disorders such as congenital heart disease, premature aging, cancer, and other disorders. All these factors augment the upward growth of the global market for viral vector production.
Companies are involved in launching new viral platforms and are entering into collaborations, acquisitions, and funding in recent years. Thermo Fisher introduced Lentiviral Production System in May 2019, and this new system is cost-efficient and is expected to simplify researchers’ workflow. IForge Biologics raised USD 40 million Series A financing in July 2020.
Report Segmentation
By Vector
Adenovirus
Retrovirus
Adeno-Associated Virus (AAV)
Lentivirus
Others
By Workflow
Upstream Processing
Vector Amplification and Expansion
Vector Recovery/Harvesting
Downstream Processing
Purification
Fill Finish
By Application
Gene and Cell Therapy Development
Vaccine Development
Biopharmaceutical & Pharmaceutical Discovery
Biomedical Research
By End-use
Pharmaceutical & Biopharmaceutical Companies
Research Institutes
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- Western Europe
- The UK
- Germany
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Poland
- Russia
- Rest of Eastern Europe
- Asia Pacific
- China
- India
- Japan
- Australia & New Zealand
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- UAE
- Saudi Arabia
- South Africa
- Rest of MEA
- South America
- Brazil
- Argentina
- Rest of South America
Competitive Insight
Some of the major players operating in the market for Viral vector manufacturing include Addgene, Inc., Advanced BioScience Laboratories, Inc. (ABL, Inc.), Aldevron, L.L.C., Audentes Therapeutics, Batavia Biosciences B.V., BioMarin Pharmaceutical, BioNTech IMFS GmbH, Biovion oy, BlueBird Bio, Catalent Inc., Cell and Gene Therapy Catapult, CEVEC Pharmaceuticals GmbH, Cobra Biologics Ltd., Creative Biogene, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., General Electric Company (GE Healthcare), Genezen, Lonza, Merck KGaA, Miltenyi Biotec GmbH, Novasep Holding S.A.S, Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.), RegenxBio, Inc., SIRION Biotech GmbH, Takara Bio., Thermo Fisher Scientific, VGXI, Inc., Vibalogics GmbH, Vigene Biosciences, Inc., Virovek Incorporation, VIVEbiotech S.L., Waisman Biomanufacturing, Wuxi AppTec Co., Ltd., YPOSKESI.
Table of Content
Chapter 1: Global Viral Vector Manufacturing Industry Overview
Chapter 3: Market Dynamics
Chapter 4: Top Company Profiles
Chapter 5: Global Viral Vector Manufacturing market Competition, by Players
Chapter 6: Global Market Size by Regions
Chapter 7: Global Market Segment by Application
Chapter 8: Global Viral Vector Manufacturing Industry Segment by Type
Chapter 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Chapter 10: Strategies and key policies by Distributors/Suppliers/Traders
Chapter 11: Key Marketing Strategy Analysis, by Market Vendors
Chapter 12: Market Effect Factors Analysis
Chapter 13: Global Viral Vector Manufacturing market Size Forecast (2023-2032).
Continue….
Reasons to Buy This Report
(A) The research provides valuable insights for top administration, policymakers, professionals, product advancements, sales managers, and stakeholders in the market. It helps them make informed decisions and strategize effectively.
(B) The report offers comprehensive analysis of Viral Vector Manufacturing market revenues on a global, regional, and country level, projecting trends until 2032. This data allows companies to assess their market share, identify growth opportunities, and explore new markets.
(C) The research includes segmentation of the Viral Vector Manufacturing market based on types, applications, technologies, and end-uses. This segmentation enables leaders to plan their products and allocate resources based on the expected growth rates of each segment.
(D) Analysis of the Viral Vector Manufacturing market benefits investors by providing insights into market scope, position, key drivers, challenges, restraints, expansion opportunities, and potential threats. This information helps them make informed investment decisions.
(E) The report offers a detailed analysis of competitors, their key strategies, and market positioning. This knowledge allows businesses to better understand the competition and plan their own strategies accordingly.
(F) The study helps evaluate Viral Vector Manufacturing business predictions by region, key countries, and top companies, providing valuable information for investment planning and decision-making.
About Report Ocean:
Report Ocean is a renowned provider of market research reports, offering high-quality insights to clients in various industries. Their goal is to assist clients in achieving their top line and bottom line objectives, thereby enhancing their market share in today’s competitive environment. As a trusted source for innovative market research reports, Report Ocean serves as a comprehensive solution for individuals, organizations, and industries seeking valuable market intelligence.